International Journal of Biological Macromolecules Submission Guide: Elsevier Portal & Tightened Scope

Source: IJBM on ScienceDirect, Clarivate JCR 2024, SciRev community data, accessed May 2026.

This is the single most-skipped piece of IJBM submission advice in 2026:

In 2024 to 2025, IJBM's editorial team tightened scope enforcement in response to concerns about high-volume publication. The post-policy editorial discipline applies stricter scope filters:

• Macromolecule-as-protagonist rule: the biological macromolecule must be the protagonist, not peripheral. Pure polymer chemistry or organic chemistry with macromolecule mention routes to specialty chemistry venues.

• Structure-function evidence required: pure synthesis or pure structural characterization without biological function demonstration auto-rejects at desk. The structure-function connection must be demonstrated, not asserted.

• Sub-5-kDa or historical-methods-only auto-out: post-2024 enforcement excludes molecules below 5 kDa and characterization using only historical methods (no modern biophysical characterization).

The desk-rejection rate has risen to ~25 to 30 percent under post-2024 enforcement, mostly in week 1. Elsevier's scope page lists exclusions but does not state the enforcement shift; this guide names it explicitly.

IJBM publishes three article types with Elsevier conventions:

• Research Article: ~6000 words including tables but excluding abstract, references, and supplementary material (post-2024 cap)

• Review article: comprehensive treatment, typical 8000 to 10000 words

• Short Communication: ~3000 words for focused contributions

Highlights mandatory: 3 to 5 bullets at no more than 85 characters each. Graphical Abstract required at >=531 × 1328 px and 300 dpi. Typical research article includes 6 to 8 figures or fewer with overflow to supplementary material.

Source: IJBM Guide for Authors.

IJBM's ~1.7-month median first decision reflects the post-2024 tightened editorial discipline with ~12-day desk-reject median.

Day 0: Editorial Manager submission

Submission lands in the portal. Automated checks run on Highlights formatting, graphical abstract specs, declaration completeness, and CRediT statement.

Day 1 to 3: Scope triage

The handling editor reads the cover letter, Highlights, abstract, and graphical abstract for the macromolecule-as-protagonist rule and structure-function evidence. Manuscripts failing either filter route to desk-rejection within week 1.

Day 5 to 12: Desk-rejection notification

Desk rejects arrive at the ~12-day median for the ~25 to 30 percent of submissions that fail the 2024-tightened scope enforcement. Notification is sent through Editorial Manager.

Week 2 to 3: Reviewer invitations

For manuscripts that pass scope triage, the editor invites reviewers from the Elsevier biological macromolecules pool. Assignment typically takes 1 to 2 weeks.

Week 6 to 7: First reviews return

Typically 2 to 3 reviewers per manuscript. Reports return across this window.

Week 8 to 12: First decision after review

Decision arrives at the ~1.7-month median per SciRev. Major revision is most common; minor revision for stronger submissions.

Week 12 to 16: Accept after revision

Revisions complete within 4 to 8 weeks for accepted manuscripts. Total handling time averages ~1.9 months per SciRev community data.

Source: SciRev community data for IJBM, accessed May 2026.

IJBM editors screen on three operational signals under the post-2024 tightened scope:

1. Macromolecule-as-protagonist rule. The biological macromolecule must be the central subject of the work, not a peripheral mention in pure-chemistry research. Pure polymer or organic chemistry routes to specialty chemistry venues.

1. Structure-function evidence demonstrated. The structural feature must be connected to a biological outcome through experimental demonstration, not asserted from structure alone. Structure-only or function-only work routes elsewhere.

1. Post-2024 scope enforcement. Sub-5-kDa molecules, historical-methods-only characterization, and high-volume submission patterns (that conflict with the 2024 editorial-policy tightening) auto-reject at desk.

Recent issues span protein structure-function studies, polysaccharide bioactivity and applications, nucleic acid biomacromolecules with function focus, lipid-protein and lipid-nucleic-acid complexes, biopolymer engineering with biological application, biomedical applications of macromolecules with mechanistic studies, drug delivery systems with structure-function characterization, biomaterials with macromolecular focus, and emerging methodologies in biological macromolecule research.

For specific recent papers, see IJBM on ScienceDirect.

This page handles the public submission rules; the draft still needs a journal-specific fit check. The review tells you whether your paper clears the International Journal of Biological Macromolecules fit check before upload, especially around biological macromolecule is a carrier, additive, or decoration rather than the protagonist, characterization stops at extraction, colorimetry, or bulk material tests without modern molecular evidence, and scope confusion between IJBM, Carbohydrate Polymers, Biomacromolecules, and biochemistry venues.

Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across biological-macromolecule manuscripts targeting International Journal of Biological Macromolecules, three desk-screen patterns recur under Elsevier's scope language. (Per the IJBM Guide for Authors, all papers must focus primarily on at least one named biological macromolecule, with that naming in the title, abstract, and text;

the journal excludes sub-5-kDa molecules, historical-methods-only characterization, and work where the macromolecule is not the major study component.) This is a specific rejection pattern page, not just a portal summary: Manusights submission analysis for biological-macromolecule manuscripts shows that the hidden scope filter usually appears in the title, abstract, graphical abstract, Highlights, methods, molecular-characterization table, figures, and cover letter before the editor reads the full results.

Biological macromolecule is a carrier, additive, or decoration rather than the protagonist

Across IJBM-targeted manuscripts, the most common desk-screen failure is a paper where the biological macromolecule is present but not load-bearing. The title names a hydrogel, nanocomposite, film, coating, nanoparticle, drug-delivery system, food-packaging material, extraction process, or biomedical scaffold, while the actual biological macromolecule is a carrier, filler, stabilizer, blend component, or surface modifier.

IJBM's guide explicitly excludes papers in which the structure or role of the biological macromolecule is not the major proportion of the study. Editors can see the problem in the title, abstract, graphical abstract, Highlights, methods, characterization table, and figure sequence.

Warning signs include a cover letter centered on application performance rather than macromolecule structure-function, FTIR or SEM characterization without molecular-weight or composition evidence, biological assays where the active agent is a small molecule rather than the macromolecule, and figures where the macromolecule disappears after synthesis.

These manuscripts often route better to Carbohydrate Polymers for polysaccharide material applications, Biomacromolecules for polymer-biology chemistry, Polymer for broader polymer science, Macromolecules for synthetic macromolecular chemistry, Materials Science and Engineering C-style biomaterials venues, or food-packaging journals.

The fix is to make the named biological macromolecule the protagonist in the title, abstract, Highlights, graphical abstract, methods, and results, then show how its structure, modification, interaction, or biological role drives the manuscript's main claim.

Check biological macromolecule is a carrier, additive, or decoration rather than the p before submitting to International Journal of Biological Macromolecules →

Characterization stops at extraction, colorimetry, or bulk material tests without modern molecular evidence

In Manusights reviews, the second recurring pattern is a manuscript that says "biological macromolecule" but does not characterize the macromolecule at the level IJBM expects. Elsevier's guide excludes papers where the biological macromolecule has not been characterized by modern analytical techniques, including molecular weight, and excludes routine extraction without purification and characterization.

The failing manuscript components are usually the methods, characterization table, spectra figures, molecular-weight evidence, purity controls, and supplementary information. Warning signs include only colorimetric assays, crude-yield tables, antioxidant activity alone, rheology without composition, particle-size data without molecular-structure evidence, or biological activity results where the macromolecular entity is not purified or defined.

Stronger IJBM submissions usually include molecular-weight determination, composition analysis, structural spectroscopy, chromatographic or electrophoretic purity, conformational or interaction evidence, and controls linking the macromolecule to the observed function. Without that evidence, the work often routes to extraction-technology journals, food chemistry venues, carbohydrate specialty outlets, biotechnology-method journals, or applied materials journals.

The fix is to add modern characterization and purification evidence before submission, then make the abstract and figures explain how the characterization supports the biological function or interaction claim.

Check characterization stops at extraction, colorimetry, or bulk material tests withou before submitting to International Journal of Biological Macromolecules →

Scope confusion between IJBM, Carbohydrate Polymers, Biomacromolecules, and biochemistry venues

For International Journal of Biological Macromolecules submissions, the third pattern is wrong-venue routing inside the macromolecule landscape. IJBM is not the default home for every polymer, carbohydrate, biomaterial, or biochemical assay that mentions a biological macromolecule. The distinction appears in the title, abstract, figure order, application claim, references, and cover letter.

If the manuscript is mainly polysaccharide film performance, packaging, rheology, or processing, Carbohydrate Polymers may be cleaner. If the manuscript is chemistry-protagonist design of macromolecular systems, Biomacromolecules or Macromolecules may be cleaner. If the work is fundamentally protein biochemistry, enzymology, or cell biology, Journal of Biological Chemistry, Biochimica et Biophysica Acta, or a molecular-biology journal may fit better.

If the work is a biomedical scaffold or drug-delivery system where the small molecule or device claim dominates, biomaterials or pharmaceutical-delivery venues may be more defensible. The IJBM-ready version makes one named biological macromolecule central in the title, abstract, graphical abstract, Highlights, methods, and biological-function figures.

The fix is to compare the manuscript's protagonist against the venue: if the protagonist is the biological macromolecule itself, IJBM is plausible; if the protagonist is the material application, synthesis method, food matrix, small-molecule payload, or clinical outcome, route elsewhere or rebuild the manuscript around structure-function evidence.

Check whether your International Journal of Biological Macromolecules manuscript is submission-ready →

• Polymer Degradation and Stability submission guide

• International Journal of Biological Macromolecules journal profile

• Is International Journal of Biological Macromolecules a good journal?

• Carbohydrate Polymers Submission Guide

• Biomacromolecules Submission Guide

• Polymer Submission Guide